255 related articles for article (PubMed ID: 23995618)
1. CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery.
Fennell BJ; McDonnell B; Tam AS; Chang L; Steven J; Broadbent ID; Gao H; Kieras E; Alley J; Luxenberg D; Edmonds J; Fitz LJ; Miao W; Whitters MJ; Medley QG; Guo YJ; Darmanin-Sheehan A; Autin B; Shúilleabháin DN; Cummins E; King A; Krebs MR; Grace C; Hickling TP; Boisvert A; Zhong X; McKenna M; Francis C; Olland S; Bloom L; Paulsen J; Somers W; Jensen A; Lin L; Finlay WJ; Cunningham O
MAbs; 2013; 5(6):882-95. PubMed ID: 23995618
[TBL] [Abstract][Full Text] [Related]
2. A Combination of Structural and Empirical Analyses Delineates the Key Contacts Mediating Stability and Affinity Increases in an Optimized Biotherapeutic Single-chain Fv (scFv).
Tu C; Terraube V; Tam AS; Stochaj W; Fennell BJ; Lin L; Stahl M; LaVallie ER; Somers W; Finlay WJ; Mosyak L; Bard J; Cunningham O
J Biol Chem; 2016 Jan; 291(3):1267-76. PubMed ID: 26515064
[TBL] [Abstract][Full Text] [Related]
3. Stability engineering of scFvs for the development of bispecific and multivalent antibodies.
Miller BR; Demarest SJ; Lugovskoy A; Huang F; Wu X; Snyder WB; Croner LJ; Wang N; Amatucci A; Michaelson JS; Glaser SM
Protein Eng Des Sel; 2010 Jul; 23(7):549-57. PubMed ID: 20457695
[TBL] [Abstract][Full Text] [Related]
4. Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis.
Choi BD; Gedeon PC; Kuan CT; Sanchez-Perez L; Archer GE; Bigner DD; Sampson JH
J Immunol Methods; 2013 Sep; 395(1-2):14-20. PubMed ID: 23806556
[TBL] [Abstract][Full Text] [Related]
5. Engineering of stable bispecific antibodies targeting IL-17A and IL-23.
Mabry R; Lewis KE; Moore M; McKernan PA; Bukowski TR; Bontadelli K; Brender T; Okada S; Lum K; West J; Kuijper JL; Ardourel D; Franke S; Lockwood L; Vu T; Frank A; Appleby MW; Wolf A; Reardon B; Hamacher NB; Stevens B; Lewis P; Lewis KB; Gilbertson DG; Lantry M; Julien SH; Ostrander C; Chan C; Byrnes-Blake K; Brody J; Presnell S; Meengs B; Levin SD; Snavely M
Protein Eng Des Sel; 2010 Mar; 23(3):115-27. PubMed ID: 20022918
[TBL] [Abstract][Full Text] [Related]
6. Rapid optimization and prototyping for therapeutic antibody-like molecules.
Xu L; Kohli N; Rennard R; Jiao Y; Razlog M; Zhang K; Baum J; Johnson B; Tang J; Schoeberl B; Fitzgerald J; Nielsen U; Lugovskoy AA
MAbs; 2013; 5(2):237-54. PubMed ID: 23392215
[TBL] [Abstract][Full Text] [Related]
7. Improvement of anti-Burkholderia mouse monoclonal antibody from various phage-displayed single-chain antibody libraries.
Kim HS; Lo SC; Wear DJ; Stojadinovic A; Weina PJ; Izadjoo MJ
J Immunol Methods; 2011 Sep; 372(1-2):146-61. PubMed ID: 21787781
[TBL] [Abstract][Full Text] [Related]
8. Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approach.
Lehmann A; Wixted JH; Shapovalov MV; Roder H; Dunbrack RL; Robinson MK
MAbs; 2015; 7(6):1058-71. PubMed ID: 26337947
[TBL] [Abstract][Full Text] [Related]
9. Construction and molecular characterization of mouse single-chain variable fragment antibodies against Burkholderia mallei and Burkholderia pseudomallei.
Kim HS; Tsai S; Zou N; Lo SC; Wear DJ; Izadjoo MJ
J Immunol Methods; 2011 Feb; 365(1-2):101-9. PubMed ID: 21172353
[TBL] [Abstract][Full Text] [Related]
10. A fully human scFv phage display library for rapid antibody fragment reformatting.
Li K; Zettlitz KA; Lipianskaya J; Zhou Y; Marks JD; Mallick P; Reiter RE; Wu AM
Protein Eng Des Sel; 2015 Oct; 28(10):307-16. PubMed ID: 25991864
[TBL] [Abstract][Full Text] [Related]
11. Fab-based bispecific antibody formats with robust biophysical properties and biological activity.
Wu X; Sereno AJ; Huang F; Lewis SM; Lieu RL; Weldon C; Torres C; Fine C; Batt MA; Fitchett JR; Glasebrook AL; Kuhlman B; Demarest SJ
MAbs; 2015; 7(3):470-82. PubMed ID: 25774965
[TBL] [Abstract][Full Text] [Related]
12. Parallel Evolution of Antibody Affinity and Thermal Stability for Optimal Biotherapeutic Development.
Franklin E; Cunningham O; Fennell B
Methods Mol Biol; 2018; 1827():457-477. PubMed ID: 30196511
[TBL] [Abstract][Full Text] [Related]
13. Dual display: phage selection driven by co-engagement of two targets by two different antibody fragments.
Fagète S; Botas-Perez L; Rossito-Borlat I; Adea K; Gueneau F; Ravn U; Rousseau F; Kosco-Vilbois M; Fischer N; Hartley O
Protein Eng Des Sel; 2017 Sep; 30(9):575-582. PubMed ID: 28444391
[TBL] [Abstract][Full Text] [Related]
14. Cloning and characterization of a single-chain fragment of monoclonal antibody to ACE suitable for lung endothelial targeting.
Balyasnikova IV; Berestetskaya JV; Visintine DJ; Nesterovitch AB; Adamian L; Danilov SM
Microvasc Res; 2010 Dec; 80(3):355-64. PubMed ID: 20888351
[TBL] [Abstract][Full Text] [Related]
15. [A Novel System for Discovering High-affinity Antibody Mutants That Enables Immunoassays with Higher Sensitivities -Development and Application of Clonal Array Profiling (CAP)].
Kiguchi Y
Yakugaku Zasshi; 2022; 142(11):1153-1159. PubMed ID: 36328444
[TBL] [Abstract][Full Text] [Related]
16. Selection of affinity-improved neutralizing human scFv against HBV PreS1 from CDR3 VH/VL mutant library.
Chen Y; Bai Y; Guo X; Wang W; Zheng Q; Wang F; Sun D; Li D; Ren G; Yin J
Biologicals; 2016 Jul; 44(4):271-275. PubMed ID: 27255707
[TBL] [Abstract][Full Text] [Related]
17. Combinatorial mutagenesis with alternative CDR-L1 and -H2 loop lengths contributes to affinity maturation of antibodies.
Brockmann EC; Pyykkö M; Hannula H; Khan K; Lamminmäki U; Huovinen T
N Biotechnol; 2021 Jan; 60():173-182. PubMed ID: 33039698
[TBL] [Abstract][Full Text] [Related]
18. Secretion from bacterial versus mammalian cells yields a recombinant scFv with variable folding properties.
Vendel MC; Favis M; Snyder WB; Huang F; Capili AD; Dong J; Glaser SM; Miller BR; Demarest SJ
Arch Biochem Biophys; 2012 Oct; 526(2):188-93. PubMed ID: 22230329
[TBL] [Abstract][Full Text] [Related]
19. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
20. Advances in the Production and Batch Reformatting of Phage Antibody Libraries.
Reader RH; Workman RG; Maddison BC; Gough KC
Mol Biotechnol; 2019 Nov; 61(11):801-815. PubMed ID: 31468301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
